Description:
Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents.
- Molecular Weight: 482.514
- Molecular Formula: C20H20FKN6O5
Purity: 98%
Canonical SMILES:
CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
InChI:
InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1
InChIKey: IFUKBHBISRAZTF-UHFFFAOYSA-M
- Melting Point: 155-157°C (dec.)
- Solubility: In Vitro: H2O: 25 mg/mL (51.81 mM; Need ultrasonic)DMSO : 6 mg/mL (12.43 mM; Need ultrasonic)In Vivo: 1.Add each solvent one by one: 10% DMSO >> 90% corn oilSolubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution2.Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% salineSolubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution3.Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution
- Appearance: White crystalline powder
- Application: Anti-HIV Agents
- Storage: Powder: -20°C: 3 years4°C: 2 yearsIn solvent: -80°C: 6 months-20°C: 1 month
Synonyms:
MK-0518; MK 0518; MK0518; Raltegravir
More details are to be found on supplier website
